live discussion: BYM338

The next live discussion is this upcoming Monday! It will be at 10AM Mountain.

This is one you won’t want to miss if you have IBM and are interested in this possible treatment!!!

Dr. Steven Greenberg will answer questions about the Novartis drug, BYM338 Monday, Dec. 16, at Noon ET.

BYM338 was granted “breakthrough” status by the FDA because it showed promise in treating inclusion-body myositis in a small trial led by Dr. Greenberg. Recruitment is underway at multiple sites, with more sites being added. Both Dr. Greenberg and patients in the pilot study spoke at the 2013 TMA Annual Conference to capacity crowds. TMA is offering another opportunity to ask questions of Dr. Greenberg.

Next live discussion – January 16: Dr. Mozaffar is director of the Neuromuscular Center at UC Irvine Medical Center in California and is a nationally recognized expert in his field. He serves as a principal investigator and co-investigator in clinical trials of drugs for neuromuscular conditions, and is the author of many professional journal articles.  Dr. Mozaffar answers your questions about “Understanding autoimmunity”. 
TMA members are invited to submit questions in advance of the chat.

 Click here to submit your questions early.

You MUST be logged in to submit a question.  To login go  Sign in is at the right hand corner. 


When submitting questions, please be as brief as possible.  If you have more than one question, submit them separately in the question window.  Questions that are off-topic will not be answered.

Live discussions are a benefit of membership in TMA.  If you’re not already a member, Become a TMA member today to take advantage of Q & A sessions as well as many other member benefits.  Membership is free.

The discussion transcript will be available immediately following the Q & A session.  Visit the Live Discussion page under Community on the TMA homepage to view a complete list of past transcripts and upcoming discussions.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s